Intervention

Efavirenz

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 120 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials120

Recruiting1

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

Reverse Triple Negative Immune Resistant Breast CancerNCT05076682 · 2022-06-30

Metformin's Effect on Drug Metabolism in Patients With Type 2 DiabetesNCT04504045 · 2020-09-01

Dosing of Tenofovir and Efavirenz in Antiretroviral TherapyNCT02945163 · 2018-03-05

Optimization of Antiretroviral TherapyNCT02935075 · 2018-03-05

Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in BotswanaNCT03336346 · 2017-11-15

Neuropsychiatric Side Effects of Efavirenz in Children Living With HIVNCT03227653 · 2017-06-19

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected WomenNCT02722421 · 2017-04-06

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and IsoniazidNCT02832778 · 2016-11-21

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected WomenNCT02499874 · 2015-08-01

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionNCT02475915 · 2015-01-01

Risk of CV Events With EFV vs. EFV-free RegimensNCT02426866 · 2014-12-01

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With EfavirenzNCT01980342 · 2014-10-01

Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral TherapyNCT02489461 · 2014-08-05

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsNCT02164812 · 2014-07-01

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral TherapyNCT01789879 · 2014-03-04

Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV CoinfectionNCT01900015 · 2014-02-03

Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV CoinfectionNCT01147107 · 2014-02-01

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-InfectedNCT01632891 · 2014-01-10

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected PatientsNCT01886404 · 2013-12-01

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentNCT01709084 · 2013-10-02

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child TransmissionNCT01618305 · 2013-09-05

Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai PatientsNCT02421289 · 2013-04-01

A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and LactationNCT02269462 · 2012-12-01

A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)NCT01632345 · 2012-10-12

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative StressNCT01585038 · 2012-07-01

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or EfavirenzNCT01695954 · 2012-05-01

The Neurocognitive Sub-study of Encore1NCT01516060 · 2012-01-01

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected IndividualsNCT01293123 · 2011-12-01

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)NCT01516970 · 2011-11-25

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) TreatmentNCT01380080 · 2011-10-01

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)NCT01271894 · 2011-09-01

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1NCT01451333 · 2011-09-01

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic SuppressionNCT01194856 · 2010-10-01

PK TDF in Thai HIV-infected ChildrenNCT02404259 · 2010-06-01

GSK1349572 Drug Interaction Study With EfavirenzNCT01098526 · 2010-03-16

Sustiva Levels With Use of a Gel CapsuleNCT01087814 · 2010-02-01

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female VolunteersNCT01268839 · 2010-01-01

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant WomenNCT00993031 · 2009-12-15

Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited SettingsNCT00091936 · 2009-08-01

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV DiseaseNCT00775606 · 2008-10-01

Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 InfectionNCT00734344 · 2008-09-01

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125NCT00792324 · 2008-06-01

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.NCT00540449 · 2008-05-01

Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in HaitiNCT00120510 · 2007-07-01

Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TBNCT01805258 · 2007-06-01

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIVNCT00442962 · 2007-05-01

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz PharmacokineticsNCT00668395 · 2007-05-01

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in SenegalNCT00100568 · 2006-07-01

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African CommunitiesNCT00255840 · 2006-07-01

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive ParticipantsNCT00350272 · 2006-05-01

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIVNCT00545558 · 2006-04-01

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)NCT00234091 · 2006-04-01

Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual DosageNCT00556634 · 2006-04-01

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenNCT00260078 · 2006-02-01

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsNCT00118898 · 2005-09-01

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at BirthNCT00102960 · 2005-07-01

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral MedicinesNCT00110305 · 2005-06-01

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsNCT00084136 · 2005-05-01

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, ChinaNCT00100594 · 2005-05-01

Preventing Sexual Transmission of HIV With Anti-HIV DrugsNCT00074581 · 2005-02-01

Common conditions

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID) 34 Bristol-Myers Squibb 6 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 5 Glaxo Wellcome 5 Merck Sharp & Dohme LLC 4 Dupont Merck 3 Hoffmann-La Roche 3 Kirby Institute 3 St Stephens Aids Trust 3 University of Nebraska 3 Abbott 2 Gilead Sciences 2 Indiana University 2 Shanghai Public Health Clinical Center 2 Tibotec Pharmaceuticals, Ireland 2

Trial status mix

COMPLETED103

UNKNOWN6

TERMINATED5

NO_LONGER_AVAILABLE2

WITHDRAWN2

RECRUITING1

SUSPENDED1

Phase mix

PHASE232

PHASE328

PHASE423

NA19

PHASE115

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.